| NCT ID | NCT05153759 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Shift-work Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-06-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-06-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore dietary factors that influence glycemic control in night shift EMS providers and to test the feasibility of a dietary intervention among these providers.
Eligibility Criteria
Inclusion Criteria: * Emergency medical service (EMS) provider * Works night shift only for at least one year * Provides patient care as primary duty Exclusion Criteria: * Diagnosis of a metabolic disease (i.e. diabetes, prediabetes, metabolic syndrome) * Taking medication to lower blood glucose * Pregnant or planning to become pregnant * Diagnosis of kidney disease or impairment * Allergies or intolerances to study foods * Digestive disorder
Contact & Investigator
David Hostler, PhD
STUDY CHAIR
University at Buffalo
Frequently Asked Questions
Who can join the NCT05153759 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Shift-work Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05153759 currently recruiting?
Yes, NCT05153759 is actively recruiting participants. Contact the research team at teganman@buffalo.edu for enrollment information.
Where is the NCT05153759 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT05153759 clinical trial?
NCT05153759 is sponsored by State University of New York at Buffalo. The principal investigator is David Hostler, PhD at University at Buffalo. The trial plans to enroll 40 participants.